Twist Bioscience Corporation Financing Cash Flow
Twist Bioscience Corporation (TWST) reported Financing Cash Flow of $8.22 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-03
- Twist Bioscience Corporation net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $3.79M, a 107.39% increase year-over-year.
- Twist Bioscience Corporation net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $4.14M, a 29.47% increase year-over-year.
- Twist Bioscience Corporation net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $298.00K, a 98.34% decline year-over-year.
- Twist Bioscience Corporation net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $5.57M, a 53.68% increase year-over-year.
- Twist Bioscience Corporation net cash provided by (used in) financing activities for fiscal 2025 was $28.54M, a 314.22% increase from fiscal 2024.
- Twist Bioscience Corporation net cash provided by (used in) financing activities for fiscal 2024 was $6.89M, a 656.31% increase from fiscal 2023.
- Twist Bioscience Corporation net cash provided by (used in) financing activities for fiscal 2023 was $911.00K, a 99.66% decline from fiscal 2022.
- Twist Bioscience Corporation net cash provided by (used in) financing activities for fiscal 2022 was $270.53M, a 17.82% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-03 | $7.92M derived: sum of 2 quarters · filed 2026-08-03 | $8.22M 10-Q · filed 2026-08-03 | $13.80M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $4.14M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-05-04 | $4.44M 10-Q · filed 2026-05-04 | $10.01M derived: sum of 3 quarters · filed 2026-05-04 | $11.84M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $298.00K 10-Q/A · filed 2026-02-26 | $5.87M derived: sum of 2 quarters · filed 2026-02-26 | $7.70M derived: sum of 3 quarters · filed 2026-08-03 | $10.89M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-09-30 | $5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $7.40M derived: sum of 2 quarters · filed 2026-08-03 | $10.60M derived: sum of 3 quarters · filed 2026-08-03 | $28.54M 10-K · filed 2025-11-17 |
| 2025-06-30 | $1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-03 | $5.02M derived: sum of 2 quarters · filed 2026-08-03 | $22.97M 10-Q · filed 2026-08-03 | $26.59M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $3.20M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-05-04 | $21.14M 10-Q · filed 2026-05-04 | $24.77M derived: sum of 3 quarters · filed 2026-05-04 | $27.68M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $17.94M 10-Q/A · filed 2026-02-26 | $21.57M derived: sum of 2 quarters · filed 2026-02-26 | $24.48M derived: sum of 3 quarters · filed 2026-02-26 | $26.31M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-09-30 | $3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $6.54M derived: sum of 2 quarters · filed 2025-11-17 | $8.36M derived: sum of 3 quarters · filed 2025-11-17 | $6.89M 10-K · filed 2025-11-17 |
| 2024-06-30 | $2.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-04 | $4.74M derived: sum of 2 quarters · filed 2025-08-04 | $3.26M 10-Q · filed 2025-08-04 | $3.71M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-03-31 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-05 | $355.00K 10-Q · filed 2025-05-05 | $797.00K derived: sum of 3 quarters · filed 2025-11-17 | $136.00K derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-12-31 | -$1.47M 10-Q · filed 2025-02-03 | -$1.03M derived: sum of 2 quarters · filed 2025-11-17 | -$1.69M derived: sum of 3 quarters · filed 2025-11-17 | -$167.00K derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-09-30 | $442.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | -$219.00K derived: sum of 2 quarters · filed 2025-11-17 | $1.31M derived: sum of 3 quarters · filed 2025-11-17 | $911.00K 10-K · filed 2025-11-17 |
| 2023-06-30 | -$661.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-02 | $864.00K derived: sum of 2 quarters · filed 2024-08-02 | $469.00K 10-Q · filed 2024-08-02 | $1.71M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-02 | $1.13M 10-Q · filed 2024-05-02 | $2.37M derived: sum of 3 quarters · filed 2024-11-18 | $1.06M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | -$395.00K 10-Q · filed 2024-02-02 | $845.00K derived: sum of 2 quarters · filed 2024-11-18 | -$466.00K derived: sum of 3 quarters · filed 2024-11-18 | $271.15M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-09-30 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | -$71.00K derived: sum of 2 quarters · filed 2024-11-18 | $271.55M derived: sum of 3 quarters · filed 2024-11-18 | $270.53M 10-K · filed 2024-11-18 |
| 2022-06-30 | -$1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | $270.31M derived: sum of 2 quarters · filed 2023-08-07 | $269.29M 10-Q · filed 2023-08-07 | $270.87M derived: sum of 4 quarters · filed 2023-11-21 |
| 2022-03-31 | $271.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-08 | $270.61M 10-Q · filed 2023-05-08 | $272.18M derived: sum of 3 quarters · filed 2023-11-21 | $271.42M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-12-31 | -$1.01M 10-Q · filed 2023-02-07 | $564.00K derived: sum of 2 quarters · filed 2023-11-21 | -$201.00K derived: sum of 3 quarters · filed 2023-11-21 | $1.25M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-09-30 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $810.00K derived: sum of 2 quarters · filed 2023-11-21 | $2.26M derived: sum of 3 quarters · filed 2023-11-21 | $329.18M 10-K · filed 2023-11-21 |
| 2021-06-30 | -$765.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | $686.00K derived: sum of 2 quarters · filed 2022-08-08 | $327.61M 10-Q · filed 2022-08-08 | $333.18M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-06 | $328.37M 10-Q · filed 2022-05-06 | $333.95M derived: sum of 3 quarters · filed 2023-06-05 | $442.01M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | $326.92M 10-Q · filed 2022-02-09 | $332.50M derived: sum of 2 quarters · filed 2023-06-05 | $440.56M derived: sum of 3 quarters · filed 2023-06-05 | $628.60M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | $5.57M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $113.64M derived: sum of 2 quarters · filed 2023-06-05 | $301.68M derived: sum of 3 quarters · filed 2023-06-05 | $303.73M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | $108.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09 | $296.10M derived: sum of 2 quarters · filed 2021-08-09 | $298.16M 10-Q · filed 2021-08-09 | $301.09M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | $188.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-07 | $190.09M 10-Q · filed 2021-05-07 | $193.02M derived: sum of 3 quarters · filed 2021-11-23 | $277.31M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | $2.06M 10-Q · filed 2021-02-09 | $4.99M derived: sum of 2 quarters · filed 2021-11-23 | $89.27M derived: sum of 3 quarters · filed 2021-11-23 | $87.64M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-09-30 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | $87.21M derived: sum of 2 quarters · filed 2021-11-23 | $85.58M derived: sum of 3 quarters · filed 2021-11-23 | $158.58M 10-K · filed 2021-11-23 |
| 2019-06-30 | $84.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-12 | $82.65M derived: sum of 2 quarters · filed 2020-08-12 | $155.65M 10-Q · filed 2020-08-12 | $162.23M derived: sum of 4 quarters · filed 2020-11-27 |
| 2019-03-31 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-13 | $71.36M 10-Q · filed 2020-05-13 | $77.95M derived: sum of 3 quarters · filed 2020-11-27 | $102.78M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-12-31 | $73.00M 10-Q · filed 2020-02-10 | $79.58M derived: sum of 2 quarters · filed 2020-11-27 | $104.41M derived: sum of 3 quarters · filed 2020-11-27 | $159.16M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-09-30 | $6.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-27 | $31.41M derived: sum of 2 quarters · filed 2020-11-27 | $86.16M derived: sum of 3 quarters · filed 2020-11-27 | $88.82M 10-K · filed 2020-11-27 |
| 2018-06-30 | $24.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | $79.58M derived: sum of 2 quarters · filed 2019-08-09 | $82.24M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $54.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-02 | $57.41M 10-Q · filed 2019-05-02 | ||
| 2017-12-31 | $2.66M 10-Q · filed 2019-02-11 | |||
| 2017-09-30 | $63.80M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |